(S)-GNE-140 is primarily utilized in the field of medical research, particularly in the development of treatments targeting cancer. It functions as a potent inhibitor of lactate dehydrogenase A (LDHA), an enzyme that plays a critical role in the metabolism of cancer cells. By inhibiting LDHA, (S)-GNE-140 disrupts the ability of cancer cells to produce energy through glycolysis, which is essential for their growth and survival, especially in hypoxic (low oxygen) environments commonly found in tumors. This makes it a promising candidate for therapeutic strategies aimed at starving cancer cells of their energy supply, thereby inhibiting tumor progression. Its application is currently focused on preclinical studies, where it is being evaluated for efficacy, safety, and potential use in combination with other cancer therapies.